Insider Trading Alert - CCRN, IDTI And BNCN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 16, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $442.00 to $2,999,379.00.

Highlighted Stocks Traded by Insiders:

Cross Country Healthcare (CCRN) - FREE Research Report

Anenberg Vickie, who is Pres., Cross Country Staffing at Cross Country Healthcare, sold 10,756 shares at $12.00 on June 16, 2015. Following this transaction, the Pres., Cross Country Staffing owned 131,519 shares meaning that the stake was reduced by 7.56% with the 10,756-share transaction.

The shares most recently traded at $12.21, up $0.21, or 1.72% since the insider transaction. Historical insider transactions for Cross Country Healthcare go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 13,563
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 13,563
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 13,563

The average volume for Cross Country Healthcare has been 176,900 shares per day over the past 30 days. Cross Country Healthcare has a market cap of $390.8 million and is part of the services sector and diversified services industry. Shares are down 2.64% year-to-date as of the close of trading on Tuesday.

Cross Country Healthcare, Inc. provides healthcare staffing and workforce solutions in the United States. The company operates through three segments: Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. Currently, there are 3 analysts who rate Cross Country Healthcare a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CCRN - FREE

TheStreet Quant Ratings rates Cross Country Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Cross Country Healthcare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Integrated Device Technology (IDTI) - FREE Research Report

Padval Umesh, who is Director at Integrated Device Technology, sold 2,500 shares at $23.72 on June 16, 2015. Following this transaction, the Director owned 35,977 shares meaning that the stake was reduced by 6.5% with the 2,500-share transaction.

The shares most recently traded at $23.93, up $0.21, or 0.89% since the insider transaction. Historical insider transactions for Integrated Device Technology go as follows:

  • 4-Week # shares bought: 100,000
  • 4-Week # shares sold: 7,170
  • 12-Week # shares bought: 100,000
  • 12-Week # shares sold: 14,510
  • 24-Week # shares bought: 100,000
  • 24-Week # shares sold: 30,805

The average volume for Integrated Device Technology has been 2.8 million shares per day over the past 30 days. Integrated Device Technology has a market cap of $3.6 billion and is part of the technology sector and electronics industry. Shares are up 22.45% year-to-date as of the close of trading on Tuesday.

Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer. The company has a P/E ratio of 39.3. Currently, there are 4 analysts who rate Integrated Device Technology a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IDTI - FREE

TheStreet Quant Ratings rates Integrated Device Technology as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Integrated Device Technology Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BNC Bancorp (BNCN) - FREE Research Report

Montgomery W Swope Jr, who is Director at BNC Bancorp, sold 1,000 shares at $18.64 on June 16, 2015. Following this transaction, the Director owned 88,897 shares meaning that the stake was reduced by 1.11% with the 1,000-share transaction.

The shares most recently traded at $18.65, up $0.01, or 0.05% since the insider transaction. Historical insider transactions for BNC Bancorp go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 1,000

The average volume for BNC Bancorp has been 62,200 shares per day over the past 30 days. BNC Bancorp has a market cap of $602.7 million and is part of the financial sector and banking industry. Shares are up 7.5% year-to-date as of the close of trading on Tuesday.

BNC Bancorp operates as the bank holding company for Bank of North Carolina that provides commercial banking products and services to individuals, and small to medium size businesses. The stock currently has a dividend yield of 1.08%. The company has a P/E ratio of 17.8. Currently, there are 3 analysts who rate BNC Bancorp a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BNCN - FREE

TheStreet Quant Ratings rates BNC Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full BNC Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing